Clinical Efficacy And Safety Of Sublingual Immunotherapy Using Standardized Dermatophagoides Farinae Extract For Patients With Allergic Rhinitis

Objective: To study the clinical efficacy of sublingual immunotherapy usingstandardized dermatophagoides farina extract for patients with allergic rhinitis.Methods: Fifty-six patients with mite-sensitive allergic rhinitis syndromes from4to39years of age were treated sublingually with standardized dermatophagoides farinaeextract. The clinical efficacy was evaluated by monthly follow-up visits. Aftertreatment for nine months using the standardized dermatophagoides farinae extract,the rhinitis symptom scores, physical sign scores, medication scores, VAS scores wereevaluated before and after immunotherapy treatment, and the adverse reactions duringthe treatment were also assessed. SPSS17.0software was used to analyze the data.Results:The allergic rhinitis symptom scores, physical sign scores, medication scores,VAS scores were8.69±1.50,2.04±0.43,1.08±0.56,7.07±0.47respectively beforetreatment and1.87±1.44,0.56±0.60,0.24±0.40,1.54±0.61after nine months oftreatment. The differences between these scores were all significant (all P<0.01).There were no severe adverse events during the treatment, except for mild mouthcavity and gastrointestinal tract discomfort.Conclusions:Sublingual immunotherapy using standardized dermatiphagoides farinaeextract is safe and effective in the treatment of patients with allergic rhinitis.